DYADIC INTERNATIONAL INC. - COMMON STOCK

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

11 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend Industry Events in March

01 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

28 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

23 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

21 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

13 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

06 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend BIO CEO & Investor Conference and European Industry Events

01 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference

02 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Dyadic Attends Investor Events in December

30 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

29 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

20 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

08 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

Dyadic to Present at Industry Events in November

30 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

25 Oct 2023 15:30:00 By Nasdaq GlobeNewswire

Dyadic Appoints Doug Pace to Its Executive Leadership Team

09 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases

05 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Present at Industry and Investor Events in October

29 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

26 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™

19 Sep 2023 07:00:00 By Nasdaq GlobeNewswire